Revenue: As of FY2025, the actual value is USD 18.67 M.

EPS: As of FY2025, the actual value is USD -0.57.

EBIT: As of FY2025, the actual value is USD -71.63 M.

Fourth Quarter 2025 Financial Results

Segment Revenue

• Total revenue was $8.4 million, compared with $10.8 million for the same period in 2024, primarily due to a decline in license and service revenue, partially offset by an increase in milestone and royalty revenue and the addition of xPloration revenue.
  • License and milestone revenue was $5,892 thousand, down from $8,650 thousand in Q4 2024.
  • Service revenue was $2,236 thousand, down from $2,533 thousand in Q4 2024.
  • xPloration revenue was $30 thousand, up from $0 in Q4 2024.
  • Royalty revenue was $218 thousand, compared to -$379 thousand in Q4 2024.

Operational Metrics

• Research and Development Expense was $13.9 million, compared with $13.3 million for Q4 2024, due to a $3.9 million impairment charge related to certain small molecule ion channel property and equipment, partially offset by lower personnel and external expenses.
• General and Administrative Expense was $6.8 million, compared with $7.4 million for Q4 2024, primarily due to lower share-based compensation expense.
• Loss from Operations was -$15,766 thousand, compared to -$15,880 thousand for Q4 2024.
• Net Loss was -$14.2 million, compared with a net loss of -$13.1 million for Q4 2024.

Full Year 2025 Financial Results

Segment Revenue

• Total revenue for 2025 was $18.7 million, compared with $26.4 million for 2024, primarily due to decreases in license and milestone revenue and a decline in service revenue, partially offset by an additional $0.8 million in xPloration revenue.
  • License and milestone revenue was $9,771 thousand, down from $13,866 thousand in 2024.
  • Service revenue was $7,263 thousand, down from $11,949 thousand in 2024.
  • xPloration revenue was $754 thousand, up from $0 in 2024.
  • Royalty revenue was $878 thousand, up from $576 thousand in 2024.

Operational Metrics

• Cost of xPloration Revenue was $0.3 million for 2025, consisting of direct costs associated with the sale of the xPloration instrument and consumables.
• Research and Development Expense was $47.8 million, compared with $55.1 million for 2024, primarily due to lower personnel and external expenses, reduced share-based compensation, and a decline in contract research costs, partially offset by a $3.9 million impairment charge.
• General and Administrative Expense was $29.2 million, compared with $30.7 million for 2024, primarily due to lower legal fees and share-based compensation expense.
• Other Operating Income, Net was $2.5 million for 2025, reflecting a $3.0 million gain from the sale of a small molecule Kv7.2 program, partially offset by a $0.3 million increase in contingent liability expense.
• Loss from Operations was -$68,969 thousand, compared to -$74,502 thousand for 2024.
• Net Loss was -$64.8 million, compared with a net loss of -$62.0 million for 2024.

Cash Flow

• As of December 31, 2025, OmniAb had cash, cash equivalents and short-term investments totaling $54.0 million.
  • Cash and cash equivalents were $25,524 thousand, down from $27,598 thousand in 2024.
  • Short-term investments were $28,501 thousand, down from $31,836 thousand in 2024.

Unique Metrics

• As of December 31, 2025, OmniAb had 107 active partners and 407 active programs, including 32 OmniAb-derived programs in clinical development or commercialization.
• The company launched OmniUltra™ in December 2025, a transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, which also enables the isolation of picobodies™.

2026 Financial Guidance

OmniAb expects 2026 revenue to be between $25 million and $30 million. Costs and operating expenses are projected to range from $80 million to $85 million. The company anticipates ending 2026 with cash and cash equivalents in the range of $30 million to $35 million, and projects an effective tax rate of approximately 0%.